Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEL-VTD and Autologous Transplant in Relapsed Multiple Myeloma
NCT00577668Phase 2Withdrawn
- Sponsor
- University of Arkansas
- Start
- Apr 2007
- Primary completion
- Apr 2009
- Modality
- Modified Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib, thalidomide, dexamethasone and melphalan in multiple myeloma (MM), sponsored by University of Arkansas. Planned start Apr 2007; status: withdrawn.
02
Drugs
bortezomibthalidomidedexamethasonemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00577668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00577668.